Inogen [INGN] vs Abbott Laboratories [ABT] Detailed Stock Comparison

Inogen Inc.

NASDAQ
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Inogen Inc. wins in 6 metrics, Abbott Laboratories wins in 12 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Inogen Inc. Abbott Laboratories Better
P/E Ratio (TTM) -8.14 25.97 Abbott Laboratories
Price-to-Book Ratio 0.99 3.09 Inogen Inc.
Debt-to-Equity Ratio 9.09 26.79 Inogen Inc.
PEG Ratio 0.22 -1.41 Inogen Inc.
EV/EBITDA -9.16 13.74 Abbott Laboratories
Profit Margin (TTM) -6.52% 13.90% Abbott Laboratories
Operating Margin (TTM) -12.21% 16.50% Abbott Laboratories
EBITDA Margin (TTM) N/A 16.50% N/A
Return on Equity -12.43% 12.36% Abbott Laboratories
Return on Assets (TTM) -6.35% 7.52% Abbott Laboratories
Free Cash Flow (TTM) $-21.60M $7.40B Abbott Laboratories
Dividend Yield N/A 1.97% N/A
1-Year Return 0.93% -35.92% Inogen Inc.
Price-to-Sales Ratio (TTM) 0.54 3.57 Inogen Inc.
Enterprise Value $87.44M $166.96B Abbott Laboratories
EV/Revenue Ratio 0.25 3.70 Inogen Inc.
Gross Profit Margin (TTM) 43.12% N/A N/A
Revenue per Share (TTM) $13 $26 Abbott Laboratories
Earnings per Share (Diluted) $-0.86 $3.57 Abbott Laboratories
Beta (Stock Volatility) 1.71 0.78 Abbott Laboratories
Short % of Float 4.16% 1.53% Abbott Laboratories

Inogen Inc. vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

INGN
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Inogen Inc.-1.97%-7.45%-12.63%-1.46%-9.64%-8.14%
Abbott Laboratories0.02%0.35%-0.65%-23.79%-31.15%-29.97%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Inogen Inc.0.93%-40.02%-89.81%-86.81%-57.16%-57.16%
Abbott Laboratories-35.92%-17.85%-21.68%118.48%249.25%313.73%

Performance & Financial Health Analysis: Inogen Inc. vs Abbott Laboratories

MetricINGNABT
Market Information
Market Cap i$190.35M$160.70B
Market Cap CategoryMicro capLarge cap
10 Day Avg. Volume i313,10513,495,583
90 Day Avg. Volume i253,08212,934,461
Last Close$5.97$86.99
52 Week Range$5.34 - $9.13$81.97 - $139.06
% from 52W High-34.61%-37.44%
All-Time High$287.79 (Sep 10, 2018)$142.60 (Dec 27, 2021)
% from All-Time High-97.93%-39.00%
Growth Metrics
Quarterly Revenue Growth0.02%0.08%
Quarterly Earnings Growth0.02%-0.19%
Financial Health
Profit Margin (TTM) i-0.07%0.14%
Operating Margin (TTM) i-0.12%0.17%
Return on Equity (TTM) i-0.12%0.12%
Debt to Equity (MRQ) i9.0926.79
Cash & Liquidity
Book Value per Share (MRQ)$7.06$30.02
Cash per Share (MRQ)$4.39$5.14
Operating Cash Flow (TTM) i$-11,216,000$10.80B
Levered Free Cash Flow (TTM) i$-21,157,376$13.77B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend iN/A$2.40

Valuation & Enterprise Metrics Analysis: Inogen Inc. vs Abbott Laboratories

MetricINGN (Apr 24, 2026)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-8.1425.97
Forward P/E i-22.4515.29
PEG Ratio i0.22-1.41
Price to Sales (TTM) i0.543.57
Price to Book (MRQ) i0.993.09
Market Capitalization
Market Capitalization i$190.35M$160.70B
Enterprise Value i$87.44M$166.96B
Enterprise Value Metrics
Enterprise to Revenue i0.253.70
Enterprise to EBITDA i-9.1613.74
Risk & Other Metrics
Beta i1.710.78
Book Value per Share (MRQ) i$7.06$30.02

Financial Statements Comparison: Inogen Inc. vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricINGN (2025)ABT (2025)
Revenue/Sales i348.67M44.33B
Cost of Goods Sold i194.40M19.32B
COGS % of Revenue i55.8%43.6%
Gross Profit i154.27M25.01B
Gross Margin i44.2%56.4%
Research & Development i19.40M2.94B
Operating Income (EBIT) i-30.21M8.05B
Operating Margin i-8.7%18.2%
EBITDA i-9.55M12.03B
EBITDA Margin i-2.7%27.1%
Pre-Tax Income i-23.38M8.47B
Pre-Tax Income % of Revenue i-6.7%19.1%
Income Tax i-632,0001.94B
Income Tax % of Revenue i-0.2%4.4%
Net Income (Profit) i-22.75M6.52B
Profit Margin i-6.5%14.7%

Balance Sheet & Liquidity Metrics

MetricINGN (2025)ABT (2025)
Cash & Equivalents i103.73M8.52B
Total Current Assets i198.30M26.00B
Total Current Assets % of Revenue i56.9%58.6%
Total Current Liabilities i63.54M16.50B
Total Current Liabilities % of Revenue i18.2%37.2%
Long-Term Debt i14.31M10.83B
Long-Term Debt % of Revenue i4.1%24.4%
Total Shareholders Equity i192.23M52.77B
Retained Earnings i-175.58M49.78B
Retained Earnings % of Revenue i-50.4%112.3%
Property, Plant & Equipment i101.83M17.57B

Cash Flow Statement Comparison

MetricINGN (2025)ABT (2025)
Operating Cash Flow i-16.25M10.80B
Operating Cash Flow % of Revenue i-4.7%24.4%
Capital Expenditures i-10.38M-2.17B
Free Cash Flow i-21.60M7.40B
FCF Margin i-6.2%16.7%
Debt Repayment iN/A-1.50B
Common Stock Repurchase iN/A-893.00M

Short Interest & Institutional Ownership Analysis

MetricINGNABT
Shares Short i1.12M23.83M
Short Ratio i4.291.93
Short % of Float i4.16%1.53%
Shares Outstanding i27.23M1.74B
Float Shares i24.03M1.73B
% Held by Insiders i11.97%0.54%
% Held by Institutions i76.68%82.23%
% Held by Public i11.35%17.23%

Dividend Analysis & Yield Comparison: Inogen Inc. vs Abbott Laboratories

MetricINGNABT
Last 12-Month Dividend iN/A$2.40
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend iN/A$2.24
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends iN/A$6.72
Ex-Dividend DateN/AJan 15, 2026